TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Tscan Therapeutics Inc (TCRX) operate in?
Tscan Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Tscan Therapeutics Inc (TCRX) current stock price?
As of the latest data, Tscan Therapeutics Inc stock price is $0.19, with a previous close of $0.20. Tscan Therapeutics Inc lost -$0.01 in the last trading session, representing a -6.64% loss.
What is Tscan Therapeutics Inc (TCRX) current market capitalization?
Tscan Therapeutics Inc market cap is approximately 12.05 million.
What is Tscan Therapeutics Inc (TCRX) Earnings Per Share (EPS)?
The trailing EPS is -$0.91, and the forward EPS is -$0.57.
What is Tscan Therapeutics Inc (TCRX) EBITDA?
Tscan Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -28.96 million.
Does Tscan Therapeutics Inc (TCRX) pay dividends?
No. Tscan Therapeutics Inc does not pay a dividend.
How did Tscan Therapeutics Inc (TCRX) perform in its most recent earnings report?
In the last report (June 30, 2026), Tscan Therapeutics Inc posted an EPS surprise of 20.69% and a revenue surprise of -57.96%.
What is Tscan Therapeutics Inc (TCRX) beta (volatility) score?
Tscan Therapeutics Inc has a beta of 1.069, meaning its volatility is roughly in line with the market.
